Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.

Participants needed: 512
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu Healthy Life Innovation Medical Technology Co., LtdUpdated: Mar 24, 2025Locations: 5
Eligibility criteria

Subjects aged between 18 and 75 (including 18 and 75) of both genders; [+11]

The subjects has previously received first-line treatment for pancreatic adenoca... [+15]

Read more
Status: Not yet recruiting

Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.

This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the treatment of brain metastases from non-small cell lung cancer (NSCLC) .

Participants needed: 200
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu Healthy Life Innovation Medical Technology Co., LtdUpdated: Dec 4, 2024
Eligibility criteria

The age of the subject was between 18 and 75 years old (inclusive), regardless o... [+7]

Positive driver genes; [+9]

Read more
Status: Recruiting

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Unresectable BTC represents an area of unmet medical need due to its very aggressive nature, limited treatment options, and poor prognosis. This study is to evaluate the efficacy and safety of adding TTF to the established regimen of durvalumab plus GemCis for the treatment of patients with previously untreated, unresectable BTC.

Participants needed: 60
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu Healthy Life Innovation Medical Technology Co., LtdUpdated: Oct 26, 2024Locations: 1
Eligibility criteria

Willing and able to provide written informed consent for the trial. [+13]

Patients previously received systemic treatment as the first-line therapy. [+30]

Read more